303 related articles for article (PubMed ID: 32776624)
1. Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia.
Stephen S; Park YA; Chrysostomou A
Nephrology (Carlton); 2020 Nov; 25(11):845-849. PubMed ID: 32776624
[TBL] [Abstract][Full Text] [Related]
2. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
Radbel J; Narayanan N; Bhatt PJ
Chest; 2020 Jul; 158(1):e15-e19. PubMed ID: 32343968
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
4. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
Tholin B; Hauge MT; Aukrust P; Fehrle L; Tvedt TH
J Med Case Rep; 2020 Oct; 14(1):187. PubMed ID: 33054818
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
7. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
[TBL] [Abstract][Full Text] [Related]
10. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology].
Lakatos B; Gopcsa L; Gondos E; Riczu A; Várnai Z; Nagy É; Molnár E; Bekő G; Bobek I; Reményi P; Szlávik J; Sinkó J; Vályi-Nagy I
Orv Hetil; 2020 Jun; 161(26):1070-1077. PubMed ID: 32541085
[TBL] [Abstract][Full Text] [Related]
11. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B; Li M; Zhou Z; Guan X; Xiang Y
J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
[TBL] [Abstract][Full Text] [Related]
12. [Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome].
Velasco Puyó P; Moreno L; Díaz de Heredia C; Rivière JG; Soler Palacín P
An Pediatr (Engl Ed); 2020 Aug; 93(2):132-133. PubMed ID: 32593520
[No Abstract] [Full Text] [Related]
13. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology.
Mantovani Cardoso E; Hundal J; Feterman D; Magaldi J
Clin Rheumatol; 2020 Sep; 39(9):2811-2815. PubMed ID: 32720260
[TBL] [Abstract][Full Text] [Related]
14. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
[TBL] [Abstract][Full Text] [Related]
16. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].
Luo S; Yang L; Wang C; Liu C; Li D
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(2):227-231. PubMed ID: 32391669
[TBL] [Abstract][Full Text] [Related]
17. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.
Quartuccio L; Sonaglia A; McGonagle D; Fabris M; Peghin M; Pecori D; De Monte A; Bove T; Curcio F; Bassi F; De Vita S; Tascini C
J Clin Virol; 2020 Aug; 129():104444. PubMed ID: 32570043
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
19. Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.
Wang W; Liu X; Wu S; Chen S; Li Y; Nong L; Lie P; Huang L; Cheng L; Lin Y; He J
J Infect Dis; 2020 Oct; 222(9):1444-1451. PubMed ID: 32601708
[TBL] [Abstract][Full Text] [Related]
20. Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome.
Steinhardt MJ; Wiebecke S; Weismann D; Frantz S; Tony HP; Klinker H; Schmalzing M
Scand J Rheumatol; 2020 Sep; 49(5):414-416. PubMed ID: 32914670
[No Abstract] [Full Text] [Related]
[Next] [New Search]
